$MRNA did a pump-and-dump on biotech and is still up 100%. We were hoping generalists and retail would come into biotech and take us to the moon, but they came in too hard and now biotech is overvalued. I guess we just can't have nice things. $XBI
$IBRX Hanging your hat on your YoY revenue growth two years after a drug launch to cover up your QoQ growth stagnation is...not a good look. The company has flatlined at 15% QoQ growth for the last three quarters.